Avacta Group Plc (AIM: AVCT)
Health Care · Biotechnology · GB
£0.64
-11.11% today · +2.9% 1Y
Avacta Group Plc (AIM: AVCT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $445.37M.
Over the last twelve months the share price has gained 2.9%, trading between 0.48 and 0.92.
Tweenvest scores Avacta Group Plc across four factors: quality 26/100, value 37/100, growth 31/100. Its strongest factor is value.
AVCT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $445.37M
- Revenue (TTM)
- $149.93K
- P/E
- —
- EPS
- -0.09
- Dividend yield
- —
- Beta (5Y)
- -0.16
- 52-week high
- £0.92
- 52-week low
- £0.48
- Avg volume (3M)
- —
- Shares outstanding
- 468.40M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Assembly Biosciences, Inc.NasdaqGS: ASMB | $467.28M | $22.82 | -0.57% |
| SanBio Company LimitedTSE: 4592 | $465.71M | ¥941.00 | -1.05% |
| Ovid Therapeutics Inc.NasdaqCM: OVID | $460.90M | $2.34 | -0.85% |
| Kamada Ltd.TASE: KMDA | $454.57M | ₪24.18 | -0.21% |
| DiaMedica Therapeutics Inc.NasdaqCM: DMAC | $443.81M | $8.01 | -2.67% |
| Tectonic Therapeutic, Inc.NasdaqGM: TECX | $440.64M | $22.75 | +0.93% |
| Hubei Goto Biopharm Group Co., Ltd.SZSE: 300966 | $437.59M | CN¥25.70 | +0.86% |
| Myriad Genetics, Inc.NasdaqGS: MYGN | $434.25M | $4.20 | -7.49% |
Figures last refreshed Oct 4, 2026.